In tumors such as glioblastoma, ovarian, esophageal, lung, oral, prostate, and sinonasal carcinoma, SOX2 has been shown to be amplified in some subsets of patient tumors [8–19]. This evidence concerns the gene SOX2 and nasal cavity and paranasal sinus carcinoma.